Your browser doesn't support javascript.
loading
Inorganic polyphosphate: from basic research to diagnostic and therapeutic opportunities in ALS/FTD.
Garcés, Polett; Amaro, Armando; Montecino, Martin; van Zundert, Brigitte.
Afiliación
  • Garcés P; Faculty of Medicine and Faculty of Life Sciences, Institute of Biomedical Sciences (ICB), Universidad Andres Bello, Santiago, Chile.
  • Amaro A; Faculty of Medicine and Faculty of Life Sciences, Institute of Biomedical Sciences (ICB), Universidad Andres Bello, Santiago, Chile.
  • Montecino M; Faculty of Medicine and Faculty of Life Sciences, Institute of Biomedical Sciences (ICB), Universidad Andres Bello, Santiago, Chile.
  • van Zundert B; Millennium Nucleus of Neuroepigenetics and Plasticity (EpiNeuro), Santiago, Chile.
Biochem Soc Trans ; 52(1): 123-135, 2024 02 28.
Article en En | MEDLINE | ID: mdl-38323662
ABSTRACT
Inorganic polyphosphate (polyP) is a simple, negatively charged biopolymer with chain lengths ranging from just a few to over a thousand ortho-phosphate (Pi) residues. polyP is detected in every cell type across all organisms in nature thus far analyzed. Despite its structural simplicity, polyP has been shown to play important roles in a remarkably broad spectrum of biological processes, including blood coagulation, bone mineralization and inflammation. Furthermore, polyP has been implicated in brain function and the neurodegenerative diseases amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), Alzheimer's disease and Parkinson's disease. In this review, we first address the challenges associated with identifying mammalian polyP metabolizing enzymes, such as Nudt3, and quantifying polyP levels in brain tissue, cultured neural cells and cerebrospinal fluid. Subsequently, we focus on recent studies that unveil how the excessive release of polyP by human and mouse ALS/FTD astrocytes contributes to these devastating diseases by inducing hyperexcitability, leading to motoneuron death. Potential implications of elevated polyP levels in ALS/FTD patients for innovative diagnostic and therapeutic approaches are explored. It is emphasized, however, that caution is required in targeting polyP in the brain due to its diverse physiological functions, serving as an energy source, a chelator for divalent cations and a scaffold for amyloidogenic proteins. Reducing polyP levels, especially in neurons, might thus have adverse effects in brain functioning. Finally, we discuss how activated mast cells and platelets also can significantly contribute to ALS progression, as they can massively release polyP.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Enfermedad de Parkinson / Demencia Frontotemporal / Enfermedad de Alzheimer / Esclerosis Amiotrófica Lateral Tipo de estudio: Diagnostic_studies Límite: Animals / Humans Idioma: En Revista: Biochem Soc Trans Año: 2024 Tipo del documento: Article País de afiliación: Chile

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Enfermedad de Parkinson / Demencia Frontotemporal / Enfermedad de Alzheimer / Esclerosis Amiotrófica Lateral Tipo de estudio: Diagnostic_studies Límite: Animals / Humans Idioma: En Revista: Biochem Soc Trans Año: 2024 Tipo del documento: Article País de afiliación: Chile